Education

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

CMS updates CME guidance

CMS updates CME guidance

New rules will require manufacturers to report some indirect payments made to physicians for CME activities.

Private equity firm acquires CME provider

Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.

21st Century Cures, Amarin Court Case Advance

21st Century Cures, Amarin Court Case Advance

Pharma's efforts to evolve restrictions about off-label marketing move forward.

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Drug industry's CME support swings to a 2% gain

Drug industry's CME support swings to a 2% gain

Last year's increase in CME support from manufacturers came after six straight years of declining budgets.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Could Marketing in Schools Help Save America's Health?

Could Marketing in Schools Help Save America's Health?

With an eye on the bottom line, hospitals and their marketing firms traditionally haven't spent much time on school campuses.

Pioneering info portal for doctors turns 20

Pioneering info portal for doctors turns 20

Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.